{
  "company": "LUPIN",
  "report_date": "May 21, 2025",
  "filename": "LUPIN_transcript_May_2025.pdf",
  "quarter": "Q12",
  "fiscal_year": "2025",
  "management_team": [
    "MS. VINITA GUPTA - CEO, LUPIN LIMITED",
    "MR. NILESH GUPTA - MANAGING DIRECTOR, LUPIN LIMITED",
    "MR. RAMESH SWAMINATHAN - EXECUTIVE DIRECTOR, GLOBAL CFO & HEAD OF API",
    "MR. RAVI AGRAWAL - M&A AND INVESTOR RELATIONS, LUPIN LIMITED",
    "VINITA GUPTA - CEO, LUPIN LIMITED",
    "NILESH GUPTA - MANAGING DIRECTOR, LUPIN LIMITED",
    "RAMESH SWAMINATHAN - EXECUTIVE DIRECTOR, GLOBAL CFO & HEAD OF API",
    "RAVI AGRAWAL - M&A AND INVESTOR RELATIONS, LUPIN LIMITED"
  ],
  "moderator": "Moderator information not found",
  "analysts": [],
  "qa_segments": [],
  "key_financial_metrics": {
    "growth_percentage": "13"
  },
  "business_highlights": [
    "approved by the FDA, but have multiple manufacturing \nsites that are approved by the FDA, as well as other regulators that enable us \nto build our generic business.",
    "acquired the insulin brand from Lilly, \nwhich enables us to really gain the end-to-end economics on the product.",
    "acquired with very limited promotion efforts, \nso we are looking at how we can build further on this start.",
    "acquired Medisol, which gave us a very nice injectables portfolio that enables \nus to build our internal pipeline on top of this to build a business in France.",
    "acquired a few, but not of scale."
  ],
  "extraction_metadata": {
    "extraction_date": "2025-08-03T01:08:58.944160",
    "source_file": "data\\lupin\\LUPIN_transcript_May_2025.pdf",
    "text_length": 101164,
    "extraction_method": "PyMuPDF + Regex parsing + Filename analysis"
  }
}